CTOs on the Move

Aids Vaccine Advocacy Coalition

www.avac.org

 
Aids Vaccine Advocacy Coalition is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.avac.org
  • 119 W 24th St
    New York, NY USA 10011
  • Phone: 212.367.1279

Executives

Name Title Contact Details

Similar Companies

eNeura Therapeutics

eNeura Therapeutics is a Medical Device company located in 240 N. Wolfe Rd., Sunnyvale, CA, United States.

Aptose Biosciences

Aptose Biosciences is a clinical-stage biotechnology company committed to developing first-in-class targeted agents to treat life-threatening cancers.

BioLife Solutions

BioLife Solutions is a leading supplier of cell and gene therapy bioproduction tools.

WHPM Biotech

WHPM Biotech is a Irwindale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aura Biosciences

Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications. At Aura, our mission is to deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care. We are driven by our passion and commitment to science and the patients battling cancer who are relying on us to pioneer these new therapies. We are focusing the initial development of our VDC technology platform to treat tumors of high unmet need in ocular and urologic oncology. Belzupacap sarotalocan (bel-sar), our first VDC candidate, is being developed for the first-line treatment of early-stage choroidal melanoma, a rare disease with no drugs approved. Beyond early-stage choroidal melanoma, we are developing bel-sar in additional ocular oncology indications, including choroidal metastasis. Leveraging our VDCs` broad tumor targeting capabilities, we have also initiated a clinical program in non-muscle invasive bladder cancer, or NMIBC, our first non-ocular solid tumor indication.